By Topic

Detection of serum anti-p53 antibodies in cancer that uses recombined wild-type p53 protein and phage displayed peptide

Sign In

Cookies must be enabled to login.After enabling cookies , please use refresh or reload or ctrl+f5 on the browser for the login options.

Formats Non-Member Member
$31 $13
Learn how you can qualify for the best price for this item!
Become an IEEE Member or Subscribe to
IEEE Xplore for exclusive pricing!
close button

puzzle piece

IEEE membership options for an individual and IEEE Xplore subscriptions for an organization offer the most affordable access to essential journal articles, conference papers, standards, eBooks, and eLearning courses.

Learn more about:

IEEE membership

IEEE Xplore subscriptions

5 Author(s)
Dehai Yu ; Inst. of Genetics & Cytology, Northeast Normal Univ., Changchun, China ; Jinhui Li ; Jing Wu ; Li Wang
more authors

Background: Although clinical significance of serum p53 Abs (s-p53 Abs) in cancer patients has been studied during the past few years, how to detect it effectively is a crucial issue. Methods: wild-type p53 protein (wt p53) and phage-displayed peptide were prepared. Three types of enzymelinked immunosorbent assays (ELISA) methods were constructed and a hybrid antigen-ELISA approach was attempted. Results: 7 breast cancer patients (19.4%) were detected s-p53 Abs positive by p53-ELISA, 4 patients (11.1%) were detected positive by phage-ELISA, and 10 patients (27.8%) were detected positive by p53-phage ELISA. A combination of 1.5μg/ml wt p53 and 40μg/ml phage was the best concentration for a mix antigen in hybrid antigen-ELISA. Conclusion: A combination of p53-ELISA and phage-ELISA can effectively improve the sensitivity of s-p53 Abs. This increases the application possibility of s-p53 Abs on clinic.

Published in:

Computer Sciences and Convergence Information Technology (ICCIT), 2010 5th International Conference on

Date of Conference:

Nov. 30 2010-Dec. 2 2010